Edition:
United States

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

52.89USD
20 Apr 2018
Change (% chg)

$0.44 (+0.84%)
Prev Close
$52.45
Open
$52.27
Day's High
$53.15
Day's Low
$52.27
Volume
165,517
Avg. Vol
285,724
52-wk High
$81.48
52-wk Low
$44.62

Chart for

About

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal... (more)

Overall

Beta: 0.38
Market Cap(Mil.): $2,711.03
Shares Outstanding(Mil.): 51.26
Dividend: --
Yield (%): --

Financials

  NUVA.OQ Industry Sector
P/E (TTM): 45.59 35.59 33.60
EPS (TTM): 1.16 -- --
ROI: 4.41 14.13 13.19
ROE: 8.52 16.91 15.00

BRIEF-Nuvasive Posts Q4 Adj. Earnings Per Share $0.56

* NUVASIVE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 26 2018

BRIEF-John DeFord To Join NuVasive Board Of Directors

* NUVASIVE INC - AS A RESULT OF DEFORD'S APPOINTMENT, NUVASIVE BOARD OF DIRECTORS CONSISTS OF 10 DIRECTORS Source text for Eikon: Further company coverage:

Feb 08 2018

BRIEF-NuVasive Comments On Expected Impact Of U.S. Tax Reform

* NUVASIVE INC - ‍SAVINGS FROM TAX REFORM EXPECTED TO BOOST FORWARD-LOOKING FREE CASH FLOW, NON-GAAP EPS IN EXCESS OF 10 % PER YEAR BEGINNING IN 2018​

Dec 21 2017

BRIEF-Nuvasive To Acquire Safepassage

* NUVASIVE INC - NUVASIVE EXPECTS TRANSACTION TO BE ACCRETIVE TO COMPANY'S NON-GAAP EARNINGS PER SHARE (EPS) IN 2018 AND BEYOND

Dec 12 2017

BRIEF-NuVasive Inc reports Q3 GAAP earnings per share $0.64

* NuVasive Inc sees ‍revenue​ and non-GAAP revenue of $1,030 million for fy 2017

Oct 24 2017

BRIEF-NuVasive announces $100 million share repurchase program

* NuVasive Inc - ‍intends to fund repurchases under share repurchase program from cash on hand, cash generated from operations​

Oct 24 2017

Earnings vs. Estimates